Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model

By Nguyen Christine M.   Bounthavong Mark   Mendes Margaret A.S.   Christopher Melissa L.D.   Tran Josephine N.   Kazerooni Rashid   Morreale Anthony P.  

PharmacoEconomics, Vol. 30, Iss. 7, 2012-07 ,pp. : 575-593

Adis International

Access to resources Recommend Favorite

The Case of Tumour Necrosis Factor-α Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis

By Sørensen Jan  

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 289-298

Adis International

Access to resources Recommend Favorite

Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly: A Review of Their Efficacy and Safety

By Radovits Beáta J.   Kievit Wietske   Laan Roland F.J.M.  

Drugs & Aging, Vol. 26, Iss. 8, 2009-08 ,pp. : 647-664

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of TNF-α-blocking agents in the treatment of rheumatoid arthritis

By Merkesdal Sonja   Ruof Jörg   Mittendorf Thomas   Zeidler Henning  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 9, 2004-09 ,pp. : 1881-1886

Informa Healthcare

Access to resources Recommend Favorite

Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis: Pharmacokinetic Modelling Analysis of Interaction between a Soluble Target and a Drug

By Stepensky David  

Clinical Pharmacokinetics, Vol. 51, Iss. 7, 2012-07 ,pp. : 443-455

Adis International

Access to resources Recommend Favorite